Ina Research Co., Ltd.
Shin Nihon Kagaku Inari Research Center aims to be the best partner in pharmaceutical development by contributing to the realization of tomorrow's medical care through non-clinical trials. Established in 1974, the company specializes in safety evaluation and non-clinical testing for pharmaceuticals, chemicals, agricultural chemicals, and food products, with a focus on animal welfare and international standards.
Industries
Nr. of Employees
large (251-1000)
Ina Research Co., Ltd.
Products
Health Food Studies
Preclinical efficacy and safety studies for health foods and functional foods using disease model animals and GLP-compliant toxicology protocols.
SEND Support Services
Comprehensive support services covering the preparation of SEND data packages through to FDA application, including quality check and verification.
SENDトータルサポート
SENDデータパッケージの作成からFDA申請時のサポートまで、PDS社と共に顧客を支援します。
SENDデータパッケージの作成
受託試験および他施設で実施した試験のSENDデータパッケージ作成サービスです。FDA申請において提出が義務化されている全ての試験種に対応しています。
被験物質の分析
濃度確認、安定性、均一性および特性分析の分析試験をICHガイダンスなどに準拠して実施します。
医療機器の生物学的安全性試験
医療機器または原材料を対象として、各種生物学的安全性試験を行います。
Health Food Studies
Preclinical efficacy and safety studies for health foods and functional foods using disease model animals and GLP-compliant toxicology protocols.
SEND Support Services
Comprehensive support services covering the preparation of SEND data packages through to FDA application, including quality check and verification.
SENDトータルサポート
SENDデータパッケージの作成からFDA申請時のサポートまで、PDS社と共に顧客を支援します。
SENDデータパッケージの作成
受託試験および他施設で実施した試験のSENDデータパッケージ作成サービスです。FDA申請において提出が義務化されている全ての試験種に対応しています。
被験物質の分析
濃度確認、安定性、均一性および特性分析の分析試験をICHガイダンスなどに準拠して実施します。
医療機器の生物学的安全性試験
医療機器または原材料を対象として、各種生物学的安全性試験を行います。
Services
End-to-end support for creation and validation of SEND datasets and packages for regulatory submission, including participation in SEND pilot programs.
Design and execution of toxicity studies from screening to preclinical repeat-dose studies to support clinical trial initiation.
Safety testing and data provision to support GHS classification, SDS creation and REACH registration.
Execution of the series of tests required for new agrochemical and formulation registration applications.
In vivo efficacy testing using established disease models to evaluate pharmacodynamic effects across CNS, ophthalmology and other therapeutic areas.
A range of analytical laboratory services including clinical testing, histopathology, metabolism assays and bioanalysis using on-site instrumentation.
End-to-end support for creation and validation of SEND datasets and packages for regulatory submission, including participation in SEND pilot programs.
Design and execution of toxicity studies from screening to preclinical repeat-dose studies to support clinical trial initiation.
Safety testing and data provision to support GHS classification, SDS creation and REACH registration.
Execution of the series of tests required for new agrochemical and formulation registration applications.
In vivo efficacy testing using established disease models to evaluate pharmacodynamic effects across CNS, ophthalmology and other therapeutic areas.
A range of analytical laboratory services including clinical testing, histopathology, metabolism assays and bioanalysis using on-site instrumentation.
Expertise Areas
- Nonclinical safety assessment and toxicology
- Pharmacology and in vivo efficacy testing
- GLP compliance and regulatory quality assurance
- SEND data management and regulatory submission support
Key Technologies
- SEND (Standard for Exchange of Nonclinical Data)
- Good Laboratory Practice (GLP)-compliant study conduct
- AAALAC-level animal welfare standards and accreditation
- CRISPR/Cas9 genome editing for disease models
News & Updates
Inari Research Center received full accreditation from AAALAC International on March 21, 2024.
Inari Research Center received compliance notifications for GLP inspections in November 2023 for pharmaceuticals, medical devices, and regenerative medicine products.
Inari Research Center changed its company name to Shin Nihon Kagaku Inari Research Center Inc. on October 1, 2024.
Research papers published by Shin Nihon Kagaku Inari Research Center, including recent collaborations and studies.
The company received full accreditation from AAALAC International, confirming animal welfare standards.
Inari Research Center received full accreditation from AAALAC International on March 21, 2024.
Inari Research Center received compliance notifications for GLP inspections in November 2023 for pharmaceuticals, medical devices, and regenerative medicine products.
Inari Research Center changed its company name to Shin Nihon Kagaku Inari Research Center Inc. on October 1, 2024.
Research papers published by Shin Nihon Kagaku Inari Research Center, including recent collaborations and studies.
The company received full accreditation from AAALAC International, confirming animal welfare standards.